Table 1.
Relevant data on the status of viral hepatitis in Mexico and recommendations.
| Type of Hepatitis | Annual Cases (2023) | Diagnostics | Vaccines/ Schedule |
Treatment | Recommendations |
|---|---|---|---|---|---|
| A | 4242 [62] | Yes | At 12 months [63] Not mandatory |
Symptomatic [64] | Reduction of vaccination gap in adolescents and adults |
| B | 618 [62] | Yes | Hexavalent/ Monovalent [63] |
Entecavir/ Tenofovir [52] |
Use of anti-HBc and NAT testing, use of DBS, expansion of vaccination coverage, access to treatment |
| C | 3895 [62] | Yes | Null | Sofosbuvir/Velpatasvir [52] | Awareness campaigns, screening, and access to treatments |
| D | Not reported | No | Protected by vaccination against HBV | Pegylated interferon alpha [52] | Allocation of resources for research in high-risk groups |
| E | 1892 * [62] | No | Null | Symptomatic [64] | Implementation of diagnostic testing |
* Reported as “other viral hepatitis”; DBS—paper-based dried-blood sampling; [reference].